glycoprotein essential for normal haemostasis as a carrier of FVIII, for mediating platelet adhesion and aggregation, is involved in inflammation, and has a proposed 8, 9 link with angiogenesis. Patients with VWD may have reduced cardiovascular mortality due to a hypocoagulation and decreased risk of thrombosis although atherogenesis seems to be in the same order as haemostatically normal people. 10, 11 The influence of VWD on cardiovascular events has been studied in a few reports and lower rates of CVD in patients with VWD have been described. It should be noted that in these studies, no individually matched controls have been included. 13 Sanders et al 14 In Sweden, all subjects with VWD are diagnosed at one of three haemophilia comprehensive care centres and are registered nationally. The aim of the present study was to generate a nationwide estimate of the absolute and comparative burden of CVD morbidity and mortality among persons with VWD compared to a group of birthdate-and sex-matched individuals from the general population in Sweden. 
| ME THODS

| Study design, setting and participants
| Registers and data
In this study, we used several national registers available through the National Board of Health and Welfare (NBHW) and Statistics 16 Of note is that details about VWD, such as factor levels or subtypes, were not available in these registries.
| Outcomes and statistical methods
The primary study outcomes included hospitalization and mortality due to selected CVD. We defined CVD as any of the following diagnoses: coronary heart disease (CHD), pulmonary embolism, stroke and deep venous thrombosis (DVT). In addition, we estimated incidence of diabetes as a potential underlying cause of CVD. For evaluating incidence and hazard rates of CVD hospitalizations, we limited the assessment to those who were born before 1969 and thus aged 40 years or older by the end of observation. The incidence of study outcomes was estimated per 1000 person-years. We used Cox regression to estimate the hazard rate ratio (HR) of hospitalization for CVD. Repeated hospitalizations were ignored. All estimates were adjusted for birthdate, sex, diabetes and cancer. Adjustment for the latter was done as it is known that malignancies may cause bleeding as well as thromboembolic disease. We only adjusted for diabetes and cancer diagnoses which were registered prior to participant's first registered CVD hospitalization. In view of the lack of information on the type and severity of VWD in this study, we used inpatient and outpatient hospital admissions to detect participants with a phenotypic bleeding diagnosis at the hospitalization event.
We used this variable to categorize participants with VWD based on their bleeding tendency and to stratify the analysis accordingly. For analysing the second study outcome, CVD mortality, we included the entire cohort of subjects with VWD born between 1895 and 2008. Using data from cause of death register, we estimated hazard ratios for both all-cause and CVD mortality. A list of all ICD codes used for extracting data on bleeding diagnosis, cancer diagnosis and CVD hospitalizations is presented in Appendix S1.
| Ethical considerations
The CBDS register project received approval from the regional ethics committee of Lund, Sweden (registration number 241/2008).
Individual informed consent was not required and, instead, the opt-out method was used. In this method, following public announcements through mass media in Sweden, individuals who do not wish to be enrolled in the study may contact the investigator and request to be excluded. Authors received de-identified data for analysis.
| RE SULTS
Overall, this study included 2790 participants with VWD including 888 male and 1902 female individuals living in Sweden (Table 1) 
| Overall hazard ratios of hospitalization for CVD
The hazard of CVD-related hospitalization was 1.6-fold (95% CI:
1.3, 2.1) among participants with VWD with a bleeding diagnosis at hospitalization (Table 2 ). This finding was consistent in both sex groups, with males and females having 1.9-and 1.6-fold hazard ratios for hospitalization, respectively. However, among those without a bleeding diagnosis (as registered in the NPR), the hazards of CVDrelated hospitalizations were not statistically significantly different compared to controls from the general population.
3.3 | Cause-specific incidence rates and hazard ratios of hospitalization for CVD Table 3 presents the overall and sex-stratified incidence rates (per 1000 person-years) and hazard ratios of hospitalization for CVD among study participants born between 1895 and 1968. Overall, CHD and stroke were the most common CVD-related causes for hospitalization among both participants with VWD and compari- In the stratified analysis based on the history of bleeding among participants with VWD, we investigated any differences between The maximum age at the study start was 92 y. The maximum age at the end of observation was 101 y. 
| CVD-related mortality
Participants with VWD born between 1895 and 2008 had a similar hazard of all-cause mortality to the comparison group after adjusting for birthdate and sex ( Figure 2) . Overall, however, they had a 0.4-fold (95% CI: 0.3, 0.6) hazard of CVD-related mortality compared to sample from the general population. This result was consistent in both male and female groups. Thus, despite having higher hospitalization rates, persons with VWD seemed to have a lower mortality caused by CVD.
| D ISCUSS I ON
This study investigated the CVD-related mortality and hospitalization among persons with VWD compared to a reference population.
The results indicated a higher burden of CVD morbidity in VWD, especially among men. The CVD mortality, on the other hand, was lower among persons with VWD than a sample from the general population. To the authors' knowledge, this study, for the first time, has quantified the absolute and comparative CVD morbidity among persons with VWD. National coverage and population-based registries as the source of outcome data with over 20 years of observation were among the unique features and strengths of this study.
Five gender-and age-matched controls per study subject further improve the robustness of the investigation.
Sweden has a long tradition of maintaining a variety of registers with complete data for many diagnoses. In our study, the additional CVD morbidity among participants with VWD can hypothetically be explained by the ease of access to a high level of healthcare We additionally adjusted for sex in this group.
resources. In general, we did not find that a VWD diagnosis protects We found higher rates of diabetes and cancer among males with VWD in our study. One hypothesis related to excess diabetes is that persons with VWD perform less physical activity due to a higher bleeding risk but, if that was the case, it is difficult to explain why it is not different among women with VWD compared to controls as well. Cancer is likely detected earlier among patients with VWD due to the higher occurrence of bleeding caused by the malignancy.
We think that our study highlights the fact that CVD remains an important source of morbidity and mortality among patients with VWD and we must be vigilant with respect to prevention, treatment and follow-up. Prospective studies are needed for further evaluation and preparation of specific guidelines for the care of these patients.
| Limitations
We did not have access to risk factors for CVD such as smoking, obesity and family history, so we could not adjust for them. Another The incidence rates were unadjusted, the sex-specific HR estimates were adjusted for birthdate, diabetes, and cancer. HR estimates in the total sample were additionally adjusted for sex. levels in the hospitalization data by stratifying those having a bleeding diagnosis as sign of a more severe bleeding phenotype.
| CON CLUS IONS
In this nationwide, long-term register study with individually matched controls, we have been able to show that persons with VWD have a higher hospitalization rate due to CVD events.
However, the mortality rates appear lower than in the control population. The latter finding is consistent with previous studies and indicates a protective effect of the clotting factor deficiency inherited with VWD.
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